Jean Tsai, MD | |
12605 E 16th Ave, Aurora, CO 80045-2545 | |
(720) 848-0000 | |
Not Available |
Full Name | Jean Tsai |
---|---|
Gender | Female |
Speciality | Neurology |
Experience | 21 Years |
Location | 12605 E 16th Ave, Aurora, Colorado |
Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1679638829 | NPI | - | NPPES |
91075041 | Medicaid | CO |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
2084N0400X | Psychiatry & Neurology - Neurology | 47277 (Colorado) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
University Of Colorado Hospital Authority | Aurora, CO | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
University Physicians Incorporated | 3476465667 | 2657 |
News Archive
Pregnant obese women were more at risk of experiencing early and late-onset hypertensive disorders, and that risk progressively increased in women with higher body mass indexes (BMI), according to a study led by researchers at The University of Texas Health Science Center at Houston (UTHealth).
Palatin Technologies, Inc. (NYSE Amex: PTN) announced that a poster on clinical trial results with PL-3994, its product for heart failure, will be presented today at the 13th Annual Scientific Meeting of the Heart Failure Society of America in Boston.
New research on brain tumours could improve patient diagnosis and treatment options as part of a precision medicine approach. Brain tumours are the leading cause of cancer deaths in children and adults under the age of 40, with 16,000 people in the UK diagnosed with a brain tumour each year.
Genervon Biopharmaceuticals announced today that the U.S. Food and Drug Administration has granted an "orphan drug" designation to Genervon's GM604 (a.k.a. GM6) bio-drug for the treatment of Amyotrophic Lateral Sclerosis (ALS). The FDA also granted GM604 a "fast-track" designation for ALS in 2013.
Investigators reported results of SORT-OUT IV, comparing Cordis Corporation's CYPHER Sirolimus-eluting Coronary Stent and Abbott's XIENCE V Everolimus-eluting Stent in the primary endpoint of MACE (major acute coronary events) at nine months.
› Verified 1 days ago
Entity Name | Denver Health And Hospital Authority |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1477569838 PECOS PAC ID: 4688583578 Enrollment ID: O20031105000211 |
News Archive
Pregnant obese women were more at risk of experiencing early and late-onset hypertensive disorders, and that risk progressively increased in women with higher body mass indexes (BMI), according to a study led by researchers at The University of Texas Health Science Center at Houston (UTHealth).
Palatin Technologies, Inc. (NYSE Amex: PTN) announced that a poster on clinical trial results with PL-3994, its product for heart failure, will be presented today at the 13th Annual Scientific Meeting of the Heart Failure Society of America in Boston.
New research on brain tumours could improve patient diagnosis and treatment options as part of a precision medicine approach. Brain tumours are the leading cause of cancer deaths in children and adults under the age of 40, with 16,000 people in the UK diagnosed with a brain tumour each year.
Genervon Biopharmaceuticals announced today that the U.S. Food and Drug Administration has granted an "orphan drug" designation to Genervon's GM604 (a.k.a. GM6) bio-drug for the treatment of Amyotrophic Lateral Sclerosis (ALS). The FDA also granted GM604 a "fast-track" designation for ALS in 2013.
Investigators reported results of SORT-OUT IV, comparing Cordis Corporation's CYPHER Sirolimus-eluting Coronary Stent and Abbott's XIENCE V Everolimus-eluting Stent in the primary endpoint of MACE (major acute coronary events) at nine months.
› Verified 1 days ago
Entity Name | University Physicians Incorporated |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1962461889 PECOS PAC ID: 3476465667 Enrollment ID: O20031105000375 |
News Archive
Pregnant obese women were more at risk of experiencing early and late-onset hypertensive disorders, and that risk progressively increased in women with higher body mass indexes (BMI), according to a study led by researchers at The University of Texas Health Science Center at Houston (UTHealth).
Palatin Technologies, Inc. (NYSE Amex: PTN) announced that a poster on clinical trial results with PL-3994, its product for heart failure, will be presented today at the 13th Annual Scientific Meeting of the Heart Failure Society of America in Boston.
New research on brain tumours could improve patient diagnosis and treatment options as part of a precision medicine approach. Brain tumours are the leading cause of cancer deaths in children and adults under the age of 40, with 16,000 people in the UK diagnosed with a brain tumour each year.
Genervon Biopharmaceuticals announced today that the U.S. Food and Drug Administration has granted an "orphan drug" designation to Genervon's GM604 (a.k.a. GM6) bio-drug for the treatment of Amyotrophic Lateral Sclerosis (ALS). The FDA also granted GM604 a "fast-track" designation for ALS in 2013.
Investigators reported results of SORT-OUT IV, comparing Cordis Corporation's CYPHER Sirolimus-eluting Coronary Stent and Abbott's XIENCE V Everolimus-eluting Stent in the primary endpoint of MACE (major acute coronary events) at nine months.
› Verified 1 days ago
Mailing Address | Practice Location Address |
---|---|
Jean Tsai, MD Po Box 110429, Aurora, CO 80042-0429 Ph: (303) 493-7000 | Jean Tsai, MD 12605 E 16th Ave, Aurora, CO 80045-2545 Ph: (720) 848-0000 |
News Archive
Pregnant obese women were more at risk of experiencing early and late-onset hypertensive disorders, and that risk progressively increased in women with higher body mass indexes (BMI), according to a study led by researchers at The University of Texas Health Science Center at Houston (UTHealth).
Palatin Technologies, Inc. (NYSE Amex: PTN) announced that a poster on clinical trial results with PL-3994, its product for heart failure, will be presented today at the 13th Annual Scientific Meeting of the Heart Failure Society of America in Boston.
New research on brain tumours could improve patient diagnosis and treatment options as part of a precision medicine approach. Brain tumours are the leading cause of cancer deaths in children and adults under the age of 40, with 16,000 people in the UK diagnosed with a brain tumour each year.
Genervon Biopharmaceuticals announced today that the U.S. Food and Drug Administration has granted an "orphan drug" designation to Genervon's GM604 (a.k.a. GM6) bio-drug for the treatment of Amyotrophic Lateral Sclerosis (ALS). The FDA also granted GM604 a "fast-track" designation for ALS in 2013.
Investigators reported results of SORT-OUT IV, comparing Cordis Corporation's CYPHER Sirolimus-eluting Coronary Stent and Abbott's XIENCE V Everolimus-eluting Stent in the primary endpoint of MACE (major acute coronary events) at nine months.
› Verified 1 days ago
Lea C Watson, MD Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 1890 N Revere Ct, Aurora, CO 80045 Phone: 720-848-0000 | |
Robert House, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 12605 E 16th Ave, Aurora, CO 80045 Phone: 720-848-0000 | |
Ann Olincy, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 12605 E 16th Ave, Aurora, CO 80045 Phone: 720-848-0000 | |
Paul Moe, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 13123 E 16th Ave, Aurora, CO 80045 Phone: 720-777-1234 | |
Dr. Erin Schwarz, D.O. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 1537 Alton St, Aurora, CO 80010 Phone: 303-617-2300 | |
Robert Clyman, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 13123 E 16th Ave, Aurora, CO 80045 Phone: 720-777-1234 | |
Dr. Bishara Bhasi, MD Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 13123 E 16th Ave, Aurora, CO 80045 Phone: 720-848-0000 |